Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. It is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Company Growth (employees)
New Haven, US
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 26 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse

Alexion Pharmaceuticals Data and Metrics

Alexion Pharmaceuticals Financial Metrics

Alexion Pharmaceuticals's revenue was reported to be $3.1 b in FY, 2016 which is a 18% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

3.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

2.8 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

399 m

EBIT (FY, 2016)

667 m

Market capitalization (22-Jun-2017)

28.4 b

Closing share price (22-Jun-2017)


Cash (31-Dec-2016)

966 m
Alexion Pharmaceuticals's current market capitalization is $28.4 b.
FY, 2013FY, 2014FY, 2015FY, 2016


1.6 b2.2 b2.6 b3.1 b

Revenue growth, %


Cost of goods sold

233.1 m258 m

Gross profit

1.4 b2.1 b2.4 b2.8 b

Gross profit Margin, %


Operating expense total

845.8 m1.2 b1.8 b2.2 b


528 m868.7 m536.7 m667 m

EBIT margin, %


Interest expense

47.7 m97 m

Pre tax profit

498.1 m576 m

Income tax expense

353.8 m177 m

Net Income

252.9 m656.9 m144.4 m399 m
FY, 2013FY, 2014FY, 2015FY, 2016


529.9 m944 m1 b966 m


102.6 m176.4 m289.9 m375 m

Current Assets

2.2 b2.8 b2.4 b2.6 b


201.1 m392.2 m697 m1 b


254.1 m254.1 m5 b5 b

Total Assets

3.3 b4.2 b13.1 b13.3 b

Accounts Payable

21.6 m44 m57.4 m64 m

Current Liabilities

582.4 m606.7 m718.3 m823 m

Additional Paid-in Capital

2.1 b2.6 b7.7 b8 b

Retained Earnings

379.1 m1 b1.2 b1.8 b

Total Equity

2.4 b3.3 b8.3 b8.7 b

Financial Leverage

1.4 x1.3 x1.6 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

252.9 m656.9 m144.4 m399 m

Depreciation and Amortization

28.7 m46.9 m166.6 m396 m

Accounts Receivable

(120 m)(28 m)(120 m)(120 m)


126 k(67 m)(88 m)(84 m)

Cash From Operating Activities

497.3 m640.1 m675.2 m1.1 b

Purchases of PP&E

(29.3 m)(136.7 m)(286.3 m)(333 m)

Cash From Investing Activities

(1 b)(222.9 m)(3.6 b)(287 m)

Cash From Financing Activities

71.6 m7.1 m3 b(836 m)

Interest Paid

2.8 m1.9 m41.4 m80 m

Income Taxes Paid

76.2 m91.2 m123.2 m38 m
Numbers are in $, USDY, 2016


1 m

Financial Leverage

1.5 x

Alexion Pharmaceuticals Market Value History

Alexion Pharmaceuticals Median Salaries

Source: 33 public H-1B filings from Alexion Pharmaceuticals

Alexion Pharmaceuticals Online and Social Media Presence

Alexion Pharmaceuticals News and Updates

Alexion Pharmaceuticals Company Life and Culture

You may also be interested in